Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784913 | 1.00 | MAPK14 (0.40) | MAPK14MAPTNR1H4POLBALDH1A1 | |
| SCHEMBL785239 | 0.89 | MAPT (0.36) | MAPTNR1H4POLBALDH1A1 | |
| SCHEMBL785025 | 0.89 | MAPT (0.36) | MAPTNR1H4POLBALDH1A1 | |
| SCHEMBL785375 | 0.84 | MAPT (0.38) | MAPK14MAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL785374 | 0.84 | MAPT (0.38) | MAPK14MAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL876338 | 0.83 | MAPT (0.35) | MAPTPOLBALDH1A1 | |
| SCHEMBL785796 | 0.79 | MAPT (0.40) | MAPK14MAPTALDH1A1 | |
| SCHEMBL484526 | 0.79 | MAPT (0.40) | MAPK14MAPTALDH1A1 | |
| SCHEMBL785419 | 0.78 | BDKRB1 (0.39) | POLB | |
| SCHEMBL2816793 | 0.78 | MAPT (0.40) | MAPK14MAPTPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | MAPK14 2793/4885MAPT 3149/4885NR1H4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.